Drug intelligence / Profile preview

KU-0060648

Development stage
Preclinical
Lead developer
University of Newcastle
Modality
Small Molecules
Administration
Oral
01

Overview

KU-0060648 is a potent, dual small molecule inhibitor of **DNA-dependent protein kinase (DNA-PK)** and **phosphoinositide 3-kinases (PI3Ks)**, showing highest potency against the PI3Kδ isoform and substantial activity against DNA-PK and other class I PI3K isoforms (PI3Kα, PI3Kβ)[1][3][5][8]. It selectively blocks the repair of DNA double-strand breaks by inhibiting DNA-PK, interfering with non-homologous end joining (NHEJ) repair, and suppresses the PI3K/AKT pathway involved in cellular growth and survival[1][3][5][8]. The compound was designed as an anti-cancer agent; it inhibits proliferation in multiple cancer cell lines (notably MCF7 breast cancer and LoVo colon cancer), both as a single agent and as a chemosensitizer in combination with topoisomerase II poisons such as etoposide and doxorubicin[1][3][5]. It demonstrates cell-line- and context-dependent anti-tumor activity and enhances the efficacy of DNA-damaging chemotherapies[1]. KU-0060648 has also been used to improve CRISPR/Cas9-mediated homology-directed repair by inhibiting NHEJ and favoring homologous recombination[3].

02

Targets

PIK3CA (Phosphoinositide 3-kinase alpha)PIK3CB (Phosphatidylinositol 3-kinase beta subunit)PIK3CD (Phosphatidylinositol 3-kinase delta)DNA-PK (DNA-dependent protein kinase)PIK3CG (Phosphatidylinositol 4,5-bisphosphate 3-kinase gamma)

Beyond the preview

Go deeper on KU-0060648.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Full profile access

Follow clinical development from study design and recruitment through results.

  • Trial phase
  • Status
  • Readouts

Indications & development

Full profile access

Explore development by indication, patient population, and geography.

  • Indications
  • Development status
  • Countries

Licensing & deals

Full profile access

Trace asset ownership, licensing agreements, and commercial partnerships.

  • Partners
  • Deal terms
  • Milestones

Patents & exclusivity

Full profile access

Explore the patent landscape and regulatory exclusivity around an asset.

  • Patents
  • Expiration dates
  • Exclusivity

Competitive landscape

Full profile access

Compare development programs by target, modality, and indication.

  • Competing assets
  • Targets
  • Development stage

Research & analysis

Full profile access

Connect source evidence and development news to your research questions.

  • Publications
  • News
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on KU-0060648.

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call